Zheng F, Du F, Wang W, Wang Y, et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Res Treat 2021 Oct 14. pii: 10.1007/s10549-021-06401.
PMID: 34648118